1. Pink Sheet

A Year Of Reconsiderations For US FDA Advisory Committees

 
• By Michael McCaughan

Correvio’s anti-arrhythmic vernakalant is returning to an advisory committee a dozen years after its first review, continuing a recent pattern of return visits for applications – and 12 years isn’t even close to the longest long back for US FDA panel in 2019.

Abstract New Year clock. Christmas time. New Year 2018 postcard. Antique old clock abstract fractal spiral. Watch clock abstract fractal pattern background poster post card. Few minutes to twelve. - Image

The US Food & Drug Administration will be convening an advisory committee to review Correvio Pharma Corp.’s anit-arrhythmic drug vernakalant in December – a dozen years after the Cardiovascular & Renal Drugs Advisory Committee first considered the product for approval.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers